CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. (SHE:000908)
China · Delayed Price · Currency is CNY 7.05
-0.07 (-0.98%)
May 6, 2026, 3:04 PM CST
SHE:000908 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 385.54 | 378.11 | 411.27 | 645.32 | 822.56 | 771.86 |
Other Revenue | - | - | 4.76 | 11.58 | 18.1 | 39.33 |
| 385.54 | 378.11 | 416.03 | 656.89 | 840.66 | 811.18 | |
Revenue Growth (YoY) | -7.22% | -9.12% | -36.67% | -21.86% | 3.63% | -7.60% |
Cost of Revenue | 139.98 | 140.32 | 155.08 | 197.92 | 205.82 | 323.64 |
Gross Profit | 245.57 | 237.79 | 260.95 | 458.97 | 634.83 | 487.55 |
Selling, General & Admin | 253.34 | 254.53 | 249.61 | 502.89 | 591.81 | 711.34 |
Research & Development | 11.85 | 11 | 13.02 | 52.51 | 35.64 | 38.63 |
Other Operating Expenses | 1.06 | 0.15 | 9.72 | 10.77 | 11.98 | 27.36 |
Operating Expenses | 266.26 | 265.68 | 266.27 | 563.35 | 654.27 | 797.37 |
Operating Income | -20.69 | -27.89 | -5.31 | -104.38 | -19.44 | -309.83 |
Interest Expense | - | - | -40.34 | -41.89 | -52.23 | -85.85 |
Interest & Investment Income | 36.24 | 36.24 | 264.4 | 5.3 | 1.12 | 249.89 |
Currency Exchange Gain (Loss) | - | - | 0.03 | 0.04 | 0.15 | -0.05 |
Other Non Operating Income (Expenses) | -44.69 | -54.93 | 0.81 | 0.51 | 1.85 | -19.08 |
EBT Excluding Unusual Items | -29.33 | -46.58 | 219.6 | -140.42 | -68.54 | -164.92 |
Gain (Loss) on Sale of Investments | - | - | -1.25 | 24.81 | 13.82 | -3.79 |
Gain (Loss) on Sale of Assets | -2.75 | -2.77 | -3.36 | 7.56 | 9.8 | 55.89 |
Asset Writedown | -28.06 | -28.25 | -19.03 | -83.76 | -39.56 | -42.79 |
Legal Settlements | - | - | -20.8 | -6.12 | -15.33 | -13.72 |
Other Unusual Items | - | - | -10.62 | 3.31 | 14.17 | 13.89 |
Pretax Income | -60.14 | -77.6 | 164.53 | -194.62 | -85.63 | -155.44 |
Income Tax Expense | 3.01 | 1.44 | 5.08 | 32.84 | 9.62 | 46.2 |
Earnings From Continuing Operations | -63.16 | -79.05 | 159.45 | -227.46 | -95.25 | -201.64 |
Minority Interest in Earnings | -2.16 | -1.84 | -7.14 | -8.64 | -27.31 | 37.98 |
Net Income | -65.32 | -80.89 | 152.3 | -236.1 | -122.56 | -163.66 |
Net Income to Common | -65.32 | -80.89 | 152.3 | -236.1 | -122.56 | -163.66 |
Shares Outstanding (Basic) | 878 | 880 | 880 | 880 | 880 | 880 |
Shares Outstanding (Diluted) | 878 | 880 | 880 | 880 | 880 | 880 |
Shares Change (YoY) | -0.69% | 0.04% | 0.02% | -0.02% | -0.01% | -0.36% |
EPS (Basic) | -0.07 | -0.09 | 0.17 | -0.27 | -0.14 | -0.19 |
EPS (Diluted) | -0.07 | -0.09 | 0.17 | -0.27 | -0.14 | -0.19 |
Free Cash Flow | -31.21 | 54.76 | -6.93 | 24.64 | 109.75 | 85.72 |
Free Cash Flow Per Share | -0.04 | 0.06 | -0.01 | 0.03 | 0.13 | 0.10 |
Gross Margin | 63.69% | 62.89% | 62.72% | 69.87% | 75.52% | 60.10% |
Operating Margin | -5.37% | -7.38% | -1.28% | -15.89% | -2.31% | -38.19% |
Profit Margin | -16.94% | -21.39% | 36.61% | -35.94% | -14.58% | -20.18% |
Free Cash Flow Margin | -8.09% | 14.48% | -1.67% | 3.75% | 13.05% | 10.57% |
EBITDA | 9.78 | 1.68 | 20.66 | -65.39 | 32.24 | -212.35 |
EBITDA Margin | 2.54% | 0.45% | 4.97% | -9.95% | 3.83% | -26.18% |
D&A For EBITDA | 30.47 | 29.57 | 25.98 | 38.99 | 51.68 | 97.47 |
EBIT | -20.69 | -27.89 | -5.31 | -104.38 | -19.44 | -309.83 |
EBIT Margin | -5.37% | -7.38% | -1.28% | -15.89% | -2.31% | -38.19% |
Effective Tax Rate | - | - | 3.09% | - | - | - |
Revenue as Reported | - | - | 416.03 | 656.89 | 840.66 | 811.18 |
Advertising Expenses | - | - | 3.92 | 20.6 | 49.36 | 73.33 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.